Global Lupus Therapeutic Market 2017-2021

  • ID: 4307415
  • Report
  • Region: Global
  • 82 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • ADMA Biologics
  • Bayer HealthCare
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • LFB Group
  • Novartis
  • MORE
About Lupus Therapeutic

Lupus is a chronic autoimmune disease in which the body's immune system becomes hyperactive and attacks normal, healthy tissue. This results in symptoms such as inflammation, swelling, and damage to joints, skin, kidneys, blood, the heart, and lungs. Systemic lupus erythematosus (SLE) is a major disease, which is followed by lupus nephritis at the later stages. Only one drug is approved specifically for the treatment of lupus disorders and the majority of other drugs are off-label based on symptoms. Due to a strong pipeline, the market is expected for more approved drugs for lupus disorders in future.

The analysts forecast the global lupus therapeutic market to grow at a CAGR of 9.74% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global lupus therapeutic market for 2017-2021. To calculate the market size, the report considers both generic and branded drug market.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Lupus Therapeutic Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

Key vendors
- F.Hoffmann-La Roche
- GlaxoSmithKline
- Medlmmune
- Pfizer
Other prominent vendors
- ADMA Biologics
- Amgen
- Anthera Pharmaceuticals
- Bayer HealthCare
- Biogen
- Biotest
- Bristol-Myers Squibb
- Celgene
- Immunomedics
- Kedrion Biopharma
- LFB Group
- Merck
- Novartis
- Shire
- Takeda Pharmaceuticals
- UCB
Market drivers
- High prevalence rate
- For a full, detailed list, view the full report

Market challenges
- Complexity of disease
- For a full, detailed list, view the full report

Market trends
- Regenerative therapeutic technologies
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key Market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are theKey vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • ADMA Biologics
  • Bayer HealthCare
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • LFB Group
  • Novartis
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: An overview of lupus disease

PART 06: Market landscape
  • Market overview
  • Five forces analysis
PART 07: Pipeline landscape

PART 08: Market segmentation by drug class
  • Anti-inflammatory drugs
  • Corticosteroids
  • Immunosuppressant drugs
  • Antimalarial drugs
  • BLyS-specific inhibitors
  • Biologicals
  • Others
PART 09: Geographical segmentation
  • Lupus therapeutics market in Americas
  • Lupus therapeutics market in EMEA
  • Lupus therapeutics market in APAC
PART 10: Decision framework

PART 11: Drivers and challenges
  • Market drivers
  • Market challenges
PART 12: Market trends
  • Regenerative therapeutic technologies
  • Inorganic growth strategies
  • Government initiatives
PART 13: Vendor landscape
  • Competitive scenario
PART 14: Key vendor analysis
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • MedImmune
  • Pfizer
  • Other prominent vendors
PART 15: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Signs and symptoms in SLE
Exhibit 02: Global lupus therapeutic market snapshot
Exhibit 03: Global lupus therapeutics market 2016-2021 ($ millions)
Exhibit 04: Opportunity analysis in global lupus therapeutic market
Exhibit 05: Five forces analysis
Exhibit 06: Pipeline analysis
Exhibit 07: Key clinical trials
Exhibit 08: Segmentation of global lupus therapeutic market by drug class 2016
Exhibit 09: Global lupus anti-inflammatory therapeutics market 2016-2021 ($ millions)
Exhibit 10: Global lupus corticosteroid drug market 2016-2021 ($ millions)
Exhibit 11: Global lupus immunosuppressant drugs market 2016-2021 ($ millions)
Exhibit 12: Global Iupus antimalarial drug market 2016-2021 ($ millions)
Exhibit 13: Global lupus market for BLyS-specific inhibitors drug segment 2016-2021 ($ millions)
Exhibit 14: Global lupus biologicals market 2016-2021 ($ millions)
Exhibit 15: Global Iupus other therapeutics market 2016-2021 ($ millions)
Exhibit 16: Segmentation of global lupus therapeutics market by geography 2016 and 2021
Exhibit 17: Global lupus therapeutics market revenue by geography 2016-2021 ($ millions)
Exhibit 18: Market scenario in Americas
Exhibit 19: Lupus therapeutics market in Americas 2016-2021 ($ millions)
Exhibit 20: Market scenario in EMEA
Exhibit 21: Lupus therapeutics market in EMEA 2016-2021 ($ millions)
Exhibit 22: Market scenario in APAC
Exhibit 23: Lupus therapeutic market in APAC 2016-2021 ($ millions)
Exhibit 24: Diagnostic tools for lupus disorders
Exhibit 25: Various drug classes used as off-label treatment for lupus disorders
Exhibit 26: Various complex symptoms associated with lupus disorder
Exhibit 27: Various side effects associated with lupus treatment
Exhibit 28: Pipeline of regenerative medicines for lupus disorders
Exhibit 29: Aims of action plans by CDC
Exhibit 30: Competitive structure analysis of global lupus therapeutics market 2016
Exhibit 31: Competitive factors of global lupus therapeutics market
Exhibit 32: Market penetration of various vendors worldwide 2016
Exhibit 33: Strategic success factors of companies in global lupus therapeutics market
Exhibit 34: F. Hoffmann-La Roche: Key highlights
Exhibit 35: F. Hoffmann-La Roche: Strength assessment
Exhibit 36: F. Hoffmann-La Roche: Strategy assessment
Exhibit 37: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 38: GlaxoSmithKline: Key highlights
Exhibit 39: GlaxoSmithKline: Strength assessment
Exhibit 40: GlaxoSmithKline: Strategy assessment
Exhibit 41: GlaxoSmithKline: Opportunity assessment
Exhibit 42: MedImmune: Key highlights
Exhibit 43: MedImmune: Strength assessment
Exhibit 44: MedImmune: Strategy assessment
Exhibit 45: MedImmune: Opportunity assessment
Exhibit 46: Pfizer: Key highlights
Exhibit 47: Pfizer: Strength assessment
Exhibit 48: Pfizer: Strategy assessment
Exhibit 49: Pfizer: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • ADMA Biologics
  • Bayer HealthCare
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • LFB Group
  • Novartis
  • MORE
New Report Released: – Global Lupus Therapeutic Market 2017-2021

The author of the report recognizes the following companies as the key players in the global lupus therapeutic market 2017-2021: F.Hoffmann-La Roche, GlaxoSmithKline, Medlmmune, and Pfizer.

Other Prominent Vendors in the market are: ADMA Biologics, Amgen, Anthera Pharmaceuticals, Bayer HealthCare, Biogen, Biotest, Bristol-Myers Squibb, Celgene, Immunomedics, Kedrion Biopharma, LFB Group, Merck, Novartis, Shire, Takeda Pharmaceuticals, and UCB.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is regenerative therapeutic technologies. The management of lupus using regenerative medicines is increasing, and many vendors are focusing on the development of regenerative medicines. The role of regenerative medicines in autoimmune disease is not explored completely. The recent studies showed that immunomodulation and suppression could be achieved through cellular interaction between therapeutic cells and the individual’s immune system, including anti-inflammatory T-cell responses.”

According to the report, one of the major drivers for this market is high prevalence rate. Lupus is one of the major autoimmune diseases that is associated with multiple symptoms like pain, extreme fatigue, hair loss, cognitive issues, and physical impairments, which disturbs every aspect of individual's lives.

Further, the report states that one of the major factors hindering the growth of this market is complexity of disease. Lupus is associated with multiple symptoms, which increases the complexity in individuals for diagnosis, treatment, and overall management. As per the Centers for Disease Control and Prevention (CDC), many individuals with lupus experiences severe inflammation and continuous damage, which leads to general fatigue, chronic pain, mood disturbances, poor sleep quality, and cognitive impairment. Fatigue is experienced by about 85%-92% of people living with lupus. The individuals with lupus can have a significantly lower quality of life than people with other chronic diseases due to its complexity.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • F.Hoffmann-La Roche
  • GlaxoSmithKline
  • Medlmmune
  • Pfizer
  • ADMA Biologics
  • Amgen
  • Anthera Pharmaceuticals
  • Bayer HealthCare
  • Biogen
  • Biotest
  • Bristol-Myers Squibb
  • Celgene
  • Immunomedics
  • Kedrion Biopharma
  • LFB Group
  • Merck
  • Novartis
  • Shire
  • Takeda Pharmaceuticals
  • UCB.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll